15th May 2014 12:46
LONDON (Alliance News) - Scancell Holdings PLC said Thursday that it will announce the latest data from its ongoing Phase I/II clinical trial of its SCIB1 ImmunoBody treatment for stage III/IV melanoma will be presented at the American Society of Clinical Oncology meeting in Chicago at the end of May.
The data will be presented in a poster graphic, Scancell said.
Shares in Scancell were trading up 5.5% at 33.75 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Scancell Holdings